Xenetic Biosciences, Inc. (XBIO) stock
XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3067% below fair value
$1.61+0.12 (+8.05%)
Close on Nov 17, 2026Market cap $3.77MP/E –Yield –
Xenetic Biosciences operating margin
Operating margin is operating income as a percentage of revenue.
Xenetic Biosciences's operating margin for the twelve months ending Jun 30, 2026 was -81.0%. For fiscal 2025 it was -95.2%, against -168.2% the year before. The highest annual figure on record is -47.1% in fiscal 2017.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -95.2% | +72.9 |
| FY2024 | Dec 31, 2024 | -168.2% | +9.6 |
| FY2023 | Dec 31, 2023 | -177.8% | +215.8 |
| FY2022 | Dec 31, 2022 | -393.6% | +101.5 |
| FY2021 | Dec 31, 2021 | -495.1% | +2694.7 |
| FY2020 | Dec 31, 2020 | -3189.8% | +72321.9 |
| FY2019 | Dec 31, 2019 | -75511.7% | −75464.7 |
| FY2017 | Dec 31, 2017 | -47.1% | +1534.0 |
| FY2016 | Dec 31, 2016 | -1581.0% | −719.7 |
| FY2013 | Dec 31, 2013 | -861.3% | +1299.5 |
| FY2012 | Dec 31, 2012 | -2160.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -147.1% | −24.3 |
| Q1 FY2026 | Mar 31, 2026 | -62.2% | +96.6 |
| Q4 FY2025 | Dec 31, 2025 | -81.3% | +88.1 |
| Q3 FY2025 | Sep 30, 2025 | -53.0% | +28.3 |
| Q2 FY2025 | Jun 30, 2025 | -122.8% | +61.3 |
| Q1 FY2025 | Mar 31, 2025 | -158.9% | +89.5 |
| Q4 FY2024 | Dec 31, 2024 | -169.4% | +17.5 |
| Q3 FY2024 | Sep 30, 2024 | -81.3% | +106.3 |
| Q2 FY2024 | Jun 30, 2024 | -184.1% | −0.1 |
| Q1 FY2024 | Mar 31, 2024 | -248.3% | −97.3 |
| Q4 FY2023 | Dec 31, 2023 | -186.9% | +458.0 |
| Q3 FY2023 | Sep 30, 2023 | -187.6% | +228.8 |
| Q2 FY2023 | Jun 30, 2023 | -184.1% | +379.4 |
| Q1 FY2023 | Mar 31, 2023 | -151.1% | +242.9 |
| Q2 FY2022 | Jun 30, 2022 | -644.8% | −252.7 |
| Q1 FY2022 | Mar 31, 2022 | -416.4% | +299.6 |
| Q4 FY2021 | Dec 31, 2021 | -563.4% | +242.7 |
| Q3 FY2021 | Sep 30, 2021 | -394.0% | +8666.7 |
| Q2 FY2021 | Jun 30, 2021 | -392.1% | +477.9 |
| Q1 FY2021 | Mar 31, 2021 | -716.0% | +1452.8 |
| Q4 FY2020 | Dec 31, 2020 | -806.2% | +6429.6 |
| Q3 FY2020 | Sep 30, 2020 | -9060.7% | −9119.8 |
| Q2 FY2020 | Jun 30, 2020 | -870.0% | +1765.9 |
| Q1 FY2020 | Mar 31, 2020 | -2168.8% | −2166.7 |
| Q4 FY2019 | Dec 31, 2019 | -7235.8% | – |
| Q4 FY2017 | Dec 31, 2017 | 59.1% | – |
| Q3 FY2017 | Sep 30, 2017 | -2635.9% | – |
| Q4 FY2016 | Dec 31, 2016 | -2.1% | – |
See a number that looks wrong?